A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
Status:
RECRUITING
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 1/2 study is to test the overall safety, tolerability, and effectiveness of the combination investigational drugs evofosfamide, zalifrelimab, and balstilimab in treating advanced or metastatic castration-resistant prostate cancer, pancreatic cancer, and human papilloma virus (HPV)-negative squamous cell carcinoma of the head and neck (SCCHN).